These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29447614)

  • 1. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B.
    Xu K; Liu LM; Farazi PA; Wang H; Rochling FA; Watanabe-Galloway S; Zhang JJ
    Glob Health Action; 2018; 11(1):1433987. PubMed ID: 29447614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs.
    Chotiyaputta W; Hongthanakorn C; Oberhelman K; Fontana RJ; Licari T; Lok AS
    J Viral Hepat; 2012 Mar; 19(3):205-12. PubMed ID: 22329375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to antiviral therapy in HIV or HBV-infected patients.
    Wójcik K; Piekarska A; Jabłonowska E
    Przegl Epidemiol; 2016; 70(1):27-32, 115-8. PubMed ID: 27344470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to Nucleoside/Nucleotide Analogue Treatment in Patients with Chronic Hepatitis B.
    Tütüncü EE; Güner R; Gürbüz Y; Kaya Kalem A; Öztürk B; Hasanoğlu İ; Şencan İ; Taşyaran MA
    Balkan Med J; 2017 Dec; 34(6):540-545. PubMed ID: 29215337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
    Qu J; Yu Z; Li Q; Chen Y; Xiang D; Tan L; Lei C; Bai W; Li H; Shang Q; Chen L; Hu X; Lu W; Li Z; Chen D; Wang X; Zhang C; Xiao G; Qi X; Chen J; Zhou L; Chen G; Li Y; Zeng Z; Rong G; Dong Z; Chen Y; Lou M; Wang C; Lu Y; Zhang C; Yang Y
    Trials; 2014 Nov; 15():438. PubMed ID: 25381721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
    Chotiyaputta W; Peterson C; Ditah FA; Goodwin D; Lok AS
    J Hepatol; 2011 Jan; 54(1):12-8. PubMed ID: 20888661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
    Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
    Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Hongthanakorn C; Chotiyaputta W; Oberhelman K; Fontana RJ; Marrero JA; Licari T; Lok AS
    Hepatology; 2011 Jun; 53(6):1854-63. PubMed ID: 21618260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of partial reimbursement on hepatitis B antiviral utilization and adherence.
    Qiu Q; Duan XW; Li Y; Yang LK; Chen Y; Li H; Duan ZP; Wang L
    World J Gastroenterol; 2015 Aug; 21(32):9588-97. PubMed ID: 26327766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.
    Jia J; Tang H; Ning Q; Jiang J; Dou X; Zhang M; Zhang S; Shang J; Lu W; Ye Y; Wang X; Li M; Liu J; Bo Q; Tan W;
    Antivir Ther; 2018; 23(3):201-209. PubMed ID: 29116050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real life adherence of chronic hepatitis B patients to entecavir treatment.
    van Vlerken LG; Arends P; Lieveld FI; Arends JE; Brouwer WP; Siersema PD; Janssen HL; van Erpecum KJ
    Dig Liver Dis; 2015 Jul; 47(7):577-83. PubMed ID: 25936691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
    Qian F; Qin J; Li D; Ma Z; Zhang H; Jin F; Wang W
    J Infect Dev Ctries; 2016 Sep; 10(9):996-1002. PubMed ID: 27694733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with non-adherence to HBV antiviral therapy.
    Sheppard-Law S; Zablotska-Manos I; Kermeen M; Holdaway S; Lee A; George J; Zekry A; Maher L
    Antivir Ther; 2018; 23(5):425-433. PubMed ID: 29355830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes.
    Allard NL; MacLachlan JH; Dev A; Dwyer J; Srivatsa G; Spelman T; Thompson AJ; Cowie BC
    BMC Gastroenterol; 2020 May; 20(1):140. PubMed ID: 32381025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.
    Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L
    Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos(t)ide analogue.
    Jang W; Yu SI; Sinn DH; Park SH; Park H; Park JY; Jeon TJ; Oh TH; Shin WC; Choi WC
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):195-200. PubMed ID: 24231289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.
    Velay A; Jeulin H; Eschlimann M; Malvé B; Goehringer F; Bensenane M; Frippiat JP; Abraham P; Ismail AM; Murray JM; Combet C; Zoulim F; Bronowicki JP; Schvoerer E
    J Viral Hepat; 2016 May; 23(5):387-98. PubMed ID: 26742490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.